BR112012015386A2 - composição oftálmica tópica - Google Patents

composição oftálmica tópica

Info

Publication number
BR112012015386A2
BR112012015386A2 BR112012015386A BR112012015386A BR112012015386A2 BR 112012015386 A2 BR112012015386 A2 BR 112012015386A2 BR 112012015386 A BR112012015386 A BR 112012015386A BR 112012015386 A BR112012015386 A BR 112012015386A BR 112012015386 A2 BR112012015386 A2 BR 112012015386A2
Authority
BR
Brazil
Prior art keywords
ophthalmic composition
topical ophthalmic
topical
composition
ophthalmic
Prior art date
Application number
BR112012015386A
Other languages
English (en)
Other versions
BR112012015386B8 (pt
BR112012015386B1 (pt
Inventor
Ponsati Obiols Berta
HERNÁNDEZ PASCUAL Cristina
Fernádez Carneado Jimena
Farrera Sinfreu Josep
Gómez Camilas Marc
SIMÓ CANONGE Rafael
Jordana I Lluch Ribera
Original Assignee
Bcn Peptides Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928893&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012015386(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bcn Peptides Sa filed Critical Bcn Peptides Sa
Publication of BR112012015386A2 publication Critical patent/BR112012015386A2/pt
Publication of BR112012015386B1 publication Critical patent/BR112012015386B1/pt
Publication of BR112012015386B8 publication Critical patent/BR112012015386B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012015386A 2009-12-22 2010-12-17 composição oftálmica tópica BR112012015386B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200931242A ES2362604B1 (es) 2009-12-22 2009-12-22 Formulación tópica oftálmica de péptidos.
ESP200931242 2009-12-23
PCT/EP2010/007737 WO2011076368A2 (en) 2009-12-22 2010-12-17 Topical ophthalmic peptide formulation

Publications (3)

Publication Number Publication Date
BR112012015386A2 true BR112012015386A2 (pt) 2018-07-24
BR112012015386B1 BR112012015386B1 (pt) 2021-02-23
BR112012015386B8 BR112012015386B8 (pt) 2021-05-25

Family

ID=43928893

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015386A BR112012015386B8 (pt) 2009-12-22 2010-12-17 composição oftálmica tópica

Country Status (34)

Country Link
US (1) US9216208B2 (pt)
EP (1) EP2515870B1 (pt)
JP (1) JP5920928B2 (pt)
KR (1) KR101657737B1 (pt)
CN (1) CN102753153B (pt)
AR (1) AR079683A1 (pt)
AU (1) AU2010335595B2 (pt)
BR (1) BR112012015386B8 (pt)
CA (1) CA2785104C (pt)
CL (1) CL2012001737A1 (pt)
CO (1) CO6592047A2 (pt)
CY (1) CY1117854T1 (pt)
DK (1) DK2515870T3 (pt)
ES (2) ES2362604B1 (pt)
HK (1) HK1178049A1 (pt)
HR (1) HRP20160954T1 (pt)
HU (1) HUE028193T2 (pt)
IL (1) IL220584A (pt)
LT (1) LT2515870T (pt)
MX (1) MX338323B (pt)
MY (1) MY178169A (pt)
NZ (1) NZ600627A (pt)
PL (1) PL2515870T3 (pt)
PT (1) PT2515870T (pt)
RS (1) RS54953B1 (pt)
RU (1) RU2561585C2 (pt)
SG (1) SG181727A1 (pt)
SI (1) SI2515870T1 (pt)
SM (1) SMT201600277B (pt)
TW (1) TWI548416B (pt)
UA (1) UA108484C2 (pt)
UY (1) UY33153A (pt)
WO (1) WO2011076368A2 (pt)
ZA (1) ZA201204522B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105007931B (zh) 2013-03-01 2018-04-06 瓦尔德西布伦大学医院基金会研究所 肽在视网膜神经退行性疾病,特别是在糖尿病视网膜病变早期和神经退行性变起重要作用的其它视网膜疾病的局部治疗中的应用
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途
WO2018143911A1 (en) 2017-01-31 2018-08-09 Kimberly-Clark Worldwide, Inc. Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same
WO2018211526A1 (en) * 2017-05-15 2018-11-22 Sun Pharmaceutical Industries Limited Octreotide injection
WO2021101344A1 (ko) * 2019-11-21 2021-05-27 삼진제약주식회사 안질환 예방 또는 치료용 점안 조성물
KR20230133595A (ko) * 2022-03-11 2023-09-19 한국한의약진흥원 등검은말벌독에 함유된 세로토닌의 안정성을 유지하기 위한 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
KR20000069889A (ko) * 1997-11-06 2000-11-25 오본 코퍼레이션 약물 송달을 위한 안정화된, 건조 약제 조성물 및 그것의 제조방법
CA2263042A1 (en) * 1999-02-25 2000-08-25 Robert W.A. Kuijpers Treatment of edema
EP1040837A3 (en) 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
AU2001283957A1 (en) * 2000-07-27 2002-02-13 Novartis Ag Treatment of ocular disorders with somatostatin analogues
TWI260228B (en) * 2002-12-31 2006-08-21 Ind Tech Res Inst Delivery carrier of presenting cell of somatostatin receptor
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US8871269B2 (en) 2003-07-15 2014-10-28 Evonik Corporation Method for the preparation of controlled release formulations
WO2007038687A2 (en) * 2005-09-27 2007-04-05 Aciont, Inc. Ocular administration of immunosuppressive agents
JP2010539045A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのフィブロネクチン断片(196−203)の使用
EP2886105B1 (en) * 2007-10-24 2018-12-05 Camurus Ab Controlled-release formulations

Also Published As

Publication number Publication date
AU2010335595A1 (en) 2012-07-12
IL220584A (en) 2016-10-31
EP2515870B1 (en) 2016-05-25
ZA201204522B (en) 2013-09-25
JP2013515687A (ja) 2013-05-09
CN102753153B (zh) 2015-11-25
BR112012015386B8 (pt) 2021-05-25
HRP20160954T1 (hr) 2016-10-07
CA2785104A1 (en) 2011-06-30
RS54953B1 (sr) 2016-11-30
JP5920928B2 (ja) 2016-05-18
TWI548416B (zh) 2016-09-11
UY33153A (es) 2011-06-30
PT2515870T (pt) 2016-08-29
TW201141514A (en) 2011-12-01
SMT201600277B (it) 2016-11-10
ES2362604A1 (es) 2011-07-08
US9216208B2 (en) 2015-12-22
WO2011076368A3 (en) 2012-03-15
KR20120120255A (ko) 2012-11-01
CL2012001737A1 (es) 2012-11-16
CN102753153A (zh) 2012-10-24
SG181727A1 (en) 2012-07-30
ES2362604B1 (es) 2012-06-28
WO2011076368A2 (en) 2011-06-30
EP2515870A2 (en) 2012-10-31
PL2515870T3 (pl) 2016-11-30
MX338323B (es) 2016-04-12
HK1178049A1 (zh) 2013-09-06
CY1117854T1 (el) 2017-05-17
CO6592047A2 (es) 2013-01-02
DK2515870T3 (en) 2016-09-05
AR079683A1 (es) 2012-02-15
MX2012007282A (es) 2012-10-15
US20130210728A1 (en) 2013-08-15
SI2515870T1 (sl) 2016-09-30
LT2515870T (lt) 2016-10-10
KR101657737B1 (ko) 2016-09-19
HUE028193T2 (en) 2016-12-28
RU2012126028A (ru) 2014-01-27
MY178169A (en) 2020-10-06
NZ600627A (en) 2014-08-29
BR112012015386B1 (pt) 2021-02-23
ES2587828T3 (es) 2016-10-27
UA108484C2 (en) 2015-05-12
IL220584A0 (en) 2012-08-30
RU2561585C2 (ru) 2015-08-27
CA2785104C (en) 2016-11-01
AU2010335595B2 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
BRPI1009281A2 (pt) composição oftálmica tópica
SMT201600307B (it) Composizione liposomiale
SMT201500053B (it) 2-Amminobenzimidazol-5-carbossammidi come agenti nati-infiammatori
BRPI1013588A2 (pt) composição
BRPI1008037A2 (pt) composição de espuma tópica
BR112012031667A2 (pt) composição
BR112012000528A2 (pt) composição antifúngica tópica
BRPI1006125A2 (pt) óculos
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1015474A2 (pt) composição
UY33161A (es) Composiciones plaguicidas
BRPI1004940A2 (pt) composição farmacêutica
DOP2011000396A (es) Composiciones novedosas
BR112012032683A2 (pt) composição
BRPI1015939A2 (pt) composição farmacêutica
DK2403814T3 (da) Landbrugsmæssig sammensætning
BRPI1010690A2 (pt) composições
BRPI1009465A2 (pt) Formulação
BR112012000657A2 (pt) novos azabicilohexanos
BR112012032980A2 (pt) composição
BR112012013182A2 (pt) composições tópicas germicidas
BRPI1005318A2 (pt) composição
BR112012015386A2 (pt) composição oftálmica tópica
BR112012028007A2 (pt) composição aquosa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF